

Substitute Form PTO-1595

Attorney Docket No.: 13425-064001 Client's Ref. No.: PH-01451-US

REEL: 012831 FRAME: 0801

SHEET

102076105

		O Name and address of constitution of the	
1. Name of conveying party(ies): Pharmacia AB Additional name(s) attached? □	8 - 0 2 Yes ⊠ No	Name and address of receiving party(ies): Biovitrum AB SE-112 76 Stockholm	
3. Nature of conveyance:		Sweden	Til on
 ☑ Assignment ☐ Merger ☐ Security Agreement ☐ Change of Name ☐ Other: 			
Execution Date: 11/20/2001		Additional names/addresses attached	? □ Yes 🗷 No
4. Application number(s) or patent number(s):			
If this document is being filed with a new a		ion date of the application is:	
A. Patent Application No(s).:		B: Patent No(s).:	
,		5,925,739	
	Additional numbers	s attached? ☐ Yes ☒ No	
5. Name/address of party to whom correspond			
document should be mailed:		6. Total number of applications/patents involve	ea: 1
JANIS K. FRASER, Ph.D.		7. Total fee (37 CFR §3.41): \$40	
Fish & Richardson P.C. 225 Franklin Street		☑ Enclosed ☐ Authorized to charge Deposit Account.	
Boston, Massachusetts 02110-28	304	8. Deposit Account No.: 06-1050	
		Please apply any additional charges, or any credits, to our Deposit Account No. 06-1050.	
	50.10.0	ISE THIS SPACE	
any attached copy is a true copy of to Jack Brennan	of my knowledge a	and belief, the foregoing information is true ent.	
any attached copy is a true copy of t	of my knowledge a	and belief, the foregoing information is true	
Jack Brennan Reg. No. 47,443	of my knowledge a he original docum Mahhan Signature	and belief, the foregoing information is true ent. Üpid ^O I	J002
Jack Brennan Reg. No. 47,443 Name of Person Signing 20416720.doc 2002 DBYRNE 00000022 5925739 CERTIFICATI L hereby certify	F OF MAILING BY FI under 37 CFR §1.8(a) the vith sufficient postage on	and belief, the foregoing information is true ent. Quid 1 Date	## description of the second

ASSIGNMENT

WHEREAS, Pharmacia AB (formerly named Pharmacia & Upjohn AB), a corporation duly organized and existing under the laws of Sweden and having a principal place of business at SE-112 87, Stockholm, Sweden (hereinafter "Assignor"), is the owner of the entire right, title and interest in and to a United States Patent entitled *PHARMACEUTICAL FORMULATION FOR SUBCUTANEOUS INTRAMUSCULAR OR INTRADERMAL ADMINISTRATION OF FACTOR VIII*, issued July 20, 1999, and assigned U.S. Patent Number 5,925,739 (hereinafter "Patent");

WHEREAS, Biovitrum AB, a corporation duly organized and existing under the laws of Sweden and having a principal place of business at SE-112 76, Stockholm, Sweden (hereinafter "Assignee"), is desirous of obtaining the entire right, title and interest in and to the Patent;

NOW, THEREFORE, therefore, in consideration of one dollar (\$1.00) and other good and valuable considerations paid by Assignee to Assignor, the receipt and sufficiency of which are hereby acknowledged, Assignor hereby sells, assigns and transfers to Assignee, its successors and assignees, the entire right, title and interest in and to the Patent, including the right to sue for past infringement thereof.

This assignment includes the Patent and any and all United States patent applications and patents for any inventions or improvements that are the subject of the Patent.

IN TESTIMONY WHEREOF, Assignor has caused this Assignment to be executed by its duly authorized officers.

	Pharmacia AB
2001 -11- 2 0 Date:	
	By: Harald Alm
	Title: Vice President Finance
2001 -11- 2 0	A Company
Date:	
	By: Inger Brattne
	Title: Associate General Counsel Scandinavia

Page 1 of 2

A duly authorized officer of Assign interest in and to the Patent.	nee hereby acknowledges receipt of the entire right, title and
Date:	Biovitrum AB By: Fredrik Berg Title: Vice President, General Counsel
2001 -11- 2 0 Date:	By: Ulf Lindquist Title: Vice President, Site Management

Page 2 of 2

RECORDED: 04/18/2002